ArticleFrontiers in oncology2025

Complete response of advanced HER2-amplified lung adenocarcinoma to cadonilimab combined with disitamab vedotin: a case report.

Yue Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.